glp-1 black box warning The global market is projected to hit $130 billion by 2030. These drugs are powerful — but they're being prescribed to millions who don't need them, without telling patients what happens Health Canada warns about fake

A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients

Some digital tools even combine features like shot scheduling, progress tracking, and symptom monitoring in one place

Nat Rev Drug Discov 13 , 799801 (2014)

Research published in major endocrinology journals has shown that patients prescribed GLP-1 receptor agonists do not experience higher rates of cancer diagnosis compared to those receiving other diabetes medicines

However, further comprehensive studies are crucial to validate these preliminary findings and unveil the underlying mechanisms